Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2022 Feb 22;19(2):e1003916. doi: 10.1371/journal.pmed.1003916

Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data

Fiona McQuaid 1,*, Rachel Mulholland 2, Yuma Sangpang Rai 3, Utkarsh Agrawal 4, Helen Bedford 5, J Claire Cameron 6, Cheryl Gibbons 6, Partho Roy 3, Aziz Sheikh 2, Ting Shi 2, Colin R Simpson 2,7, Judith Tait 6, Elise Tessier 3, Steve Turner 8, Jaime Villacampa Ortega 6, Joanne White 3, Rachael Wood 2,6
Editor: Lars Åke Persson9
PMCID: PMC8863286  PMID: 35192611

Abstract

Background

In 2020, the SARS-CoV-2 (COVID-19) pandemic and lockdown control measures threatened to disrupt routine childhood immunisation programmes with early reports suggesting uptake would fall. In response, public health bodies in Scotland and England collected national data for childhood immunisations on a weekly or monthly basis to allow for rapid analysis of trends. The aim of this study was to use these data to assess the impact of different phases of the pandemic on infant and preschool immunisation uptake rates.

Methods and findings

We conducted an observational study using routinely collected data for the year prior to the pandemic (2019) and immediately before (22 January to March 2020), during (23 March to 26 July), and after (27 July to 4 October) the first UK “lockdown”. Data were obtained for Scotland from the Public Health Scotland “COVID19 wider impacts on the health care system” dashboard and for England from ImmForm.

Five vaccinations delivered at different ages were evaluated; 3 doses of “6-in-1” diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B vaccine (DTaP/IPV/Hib/HepB) and 2 doses of measles, mumps, and rubella (MMR) vaccine. This represented 439,754 invitations to be vaccinated in Scotland and 4.1 million for England. Uptake during the 2020 periods was compared to the previous year (2019) using binary logistic regression analysis. For Scotland, uptake within 4 weeks of a child becoming eligible by age was analysed along with geographical region and indices of deprivation. For Scotland and England, we assessed whether immunisations were up-to-date at approximately 6 months (all doses 6-in-1) and 16 to 18 months (first MMR) of age.

We found that uptake within 4 weeks of eligibility in Scotland for all the 5 vaccines was higher during lockdown than in 2019. Differences ranged from 1.3% for first dose 6-in-1 vaccine (95.3 versus 94%, odds ratio [OR] compared to 2019 1.28, 95% confidence intervals [CIs] 1.18 to 1.39) to 14.3% for second MMR dose (66.1 versus 51.8%, OR compared to 2019 1.8, 95% CI 1.74 to 1.87). Significant increases in uptake were seen across all deprivation levels.

In England, fewer children due to receive their immunisations during the lockdown period were up to date at 6 months (6-in-1) or 18 months (first dose MMR). The fall in percentage uptake ranged from 0.5% for first 6-in-1 (95.8 versus 96.3%, OR compared to 2019 0.89, 95% CI 0.86– to 0.91) to 2.1% for third 6-in-1 (86.6 versus 88.7%, OR compared to 2019 0.82, 95% CI 0.81 to 0.83).

The use of routinely collected data used in this study was a limiting factor as detailed information on potential confounding factors were not available and we were unable to eliminate the possibility of seasonal trends in immunisation uptake.

Conclusions

In this study, we observed that the national lockdown in Scotland was associated with an increase in timely childhood immunisation uptake; however, in England, uptake fell slightly. Reasons for the improved uptake in Scotland may include active measures taken to promote immunisation at local and national levels during this period and should be explored further. Promoting immunisation uptake and addressing potential vaccine hesitancy is particularly important given the ongoing pandemic and COVID-19 vaccination campaigns.


Fiona McQuaid and colleagues assess the uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic.

Author summary

Why was this study done?

  • Early reports from multiple countries suggested that the SARS-CoV-2 (COVID-19) pandemic and associated control measures such as “lockdowns” could be detrimental to routine childhood immunisation uptake.

  • A fall in the number of children receiving their routine immunisations could leave the population vulnerable to multiple infectious diseases such as measles.

  • However, these reports generally only assessed the immediate effect within a few weeks of national lockdowns, and the longer-term impact of COVID-19 control measures on routine childhood immunisation uptake requires further evaluation.

  • It is important to understand how the pandemic affected the uptake of routine childhood immunisations in order to discover what factors influence immunisation uptake and help plan for the future.

What did the researchers do and find?

  • Information on childhood immunisation uptake is routinely collected in Scotland and England. Because of concerns about the effect of the pandemic on immunisation uptake, this information was collected in more detail and we used this to examine what happened over the lockdown period.

  • To see if there was any change in immunisation uptake, we compared the information from immediately before, during, and after the 2020 lockdown in the United Kingdom to information from the previous year (2019).

  • We found that immunisation uptake in Scotland rose significantly across lockdown, with over 7,000 more children receiving their immunisations on time compared to the previous year. In England, there was a slight fall in uptake.

What do these findings mean?

  • These findings suggest that, despite early concerns, infant and preschool immunisation uptake increased in Scotland over the lockdown period.

  • We do not yet have enough information to determine the reasons behind this positive change in Scotland or why uptake fell in England.

  • The next step is to assess what factors may have led to this apparent increase in uptake, which could improve uptake of infant and preschool immunisations beyond the pandemic.

  • Due to the type of information used, we were unable to fully explore the possibility of immunisation uptake varying by the time of year, and some potentially important details, such as ethnicity, were not available.

Introduction

The SARS-CoV-2 (COVID-19) pandemic and associated control measures such as national “lockdowns”, involving varying restrictions on leaving the home, work, and socialising, have had a profound impact on daily life and the delivery of healthcare worldwide. In the United Kingdom, a national lockdown was announced on 23 March 2020, with instructions that people should only leave their home for a limited number of “essential” reasons [1]. This was accompanied by the reconfiguration of acute healthcare services to support the anticipated influx of COVID-19 patients, cancellation of most elective activity, and pausing of screening programmes [2]. During lockdown, there was evidence of a change in healthcare-seeking behaviour—for example, in Scotland, the uptake of both emergency and elective hospital-based care dropped substantially over the lockdown period [3]. However, within child health, key routine services including childhood immunisations continued through the UK [4].

It has become increasingly apparent that younger children are at low risk of severe disease due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [5] and may be less susceptible to infection with the virus [6]. Yet the wider impact of the pandemic on children in terms of education, mental and physical health, and safeguarding is not yet fully understood and is likely to be profound [7,8]. One particular area of concern early in the lockdown period was the potential effect on the uptake of routine childhood immunisations [9]. Maintaining high population vaccine coverage is vital for both direct and indirect (via herd immunity) protection against non-COVID-19 infectious diseases.

In July 2020, the World Health Organization (WHO) warned of a potential decline in routine immunisation rates associated with the COVID-19 pandemic, citing a poll from May 2020 in which respondents from 82 countries suggested disruption to immunisation programmes was widespread [10]. Initial reports from England [11], Pakistan [12], South Africa [13], Singapore [14], and the USA [15] were concerning, suggesting a fall in children receiving their scheduled vaccinations in the very early weeks of national lockdowns, though, to the best of our knowledge, the full impact has not yet been assessed. However, the English and US studies relied on surrogate measures of vaccine uptake; number of vaccines delivered/ordered (without a corresponding denominator) [11,15] and the Singaporean study used convenience sampling with multiple assumptions for missing data [14]. Longer-term data were available from the KwaZulu-Natal Province of South Africa [13] and Sindh Province of Pakistan [12], which appeared to show some recovery after an initial fall in uptake; however, in Pakistan, part of the lockdown restrictions involved shutting down of outreach immunisation programme. The overall impact of lockdown on immunisation uptake in higher-income countries, which maintained their routine immunisation programmes, is unclear.

Given the prolonged and repeated periods of lockdown, it is important to evaluate the overall effect on childhood immunisation uptake. The aim of this study was, therefore, to provide a longer perspective than previous studies by describing the pattern of childhood immunisation uptake in Scotland and England before, during, and immediately after the first national lockdown implemented in response to the pandemic (23 March to 31 July), with comparisons to baseline data from 2019, by geographical area and socioeconomic deprivation.

Methods

Study design

This observational study took advantage of the natural experiment afforded by the COVID-19 pandemic and used routinely collected data for the year prior to the pandemic (2019) and immediately before, during, and after the first period of “lockdown” imposed by the United Kingdom and Scottish governments in 2020. Data were available for Scotland and England; however, as discussed below, variations in time points at which the data were collected precluded direct comparisons. Of note, this analysis relates to the first national lockdown, which began on 23 March 2020, with restrictions easing gradually from over June and July 2020. The prespecified analysis plan is included within the Supporting information (S1 File). Minor changes were made to the planned visualisation format of the data (from bar to line plots) to better illustrate the findings.

The vaccines chosen as indicators of preschool immunisation uptake were the hexavalent DTaP/IPV/Hib/HepB vaccine, (referred to here as “6-in-1”), which protects against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B, and the measles, mumps, and rubella vaccine (referred to as “MMR”). In the UK, the 6-in-1 vaccine is recommended at age 8 (“first dose 6-in-1”), 12 (“second dose 6-in-1”), and 16 (“third dose 6-in-1”) weeks of age, and MMR is given at 12 months (“first dose MMR”) and 3 years 4 months (“second dose MMR”) [16]. Uptake of the additional immunisations offered at the same ages (Meningococcal C, Rotavirus, and Pneumococcal) were not assessed.

For Scotland, we chose to primarily examine uptake within 4 weeks of eligibility as this represents timely uptake of vaccinations as per the recommended UK schedule [16] leading to the child being protected at the earliest recommended opportunity. All children living in Scotland who became eligible by age for any of the preschool immunisations of interest from January 2019 up to and including the week beginning 28 September 2020 were included. Of secondary interest, and to allow descriptive comparisons with data from England, we also analysed uptake at approximately 6 months (range 24 to 32 weeks) for the 6-in-1 and 16 months for the first dose MMR. For England, equivalent data on uptake within 4 weeks were not available; therefore, the analysis was conducted on uptake by six (6-in-1) or 18 months of age (first MMR), and monthly, rather than weekly, data were used.

Vaccine uptake was analysed in the following 4 time periods: 1 January to 31 December 2019 (“2019”), 1 January to week beginning 16 March 2020 (“prelockdown”), 23 March to week beginning 27 July (“lockdown”) and week beginning 3 August to week beginning 28 September 2020 inclusive (“postlockdown”). These time periods were chosen to correspond with the beginning of the first UK-wide lockdown as announced by the UK government on 23 March 2020 [1]. The end of the lockdown period is less well defined and varied both in approach and timescale between Scotland and England [17,18]. Broadly speaking, by the end of July 2020, there was a substantial reduction in “lockdown” restrictions in both countries with the opening of many nonessential businesses and limited indoor meeting between households permitted; therefore, a pragmatic approach was taken to define the lockdown period as 23 March 2020 until 31 July 2020. Children were included in the time period at which they first became eligible by age. As data from England were available by month only, the prelockdown period included January to end of March 2020.

Data sources

The Scottish data used in this paper were extracted in January 2021 from the PHS “COVID19 wider impacts on the health care system” dashboard, which is publicly accessible at https://scotland.shinyapps.io/phs-covid-wider-impact/. The dashboard includes aggregate information on immunisation uptake, including by the geographical area in which the child is living and the corresponding Scottish Index of Multiple Deprivation (SIMD) (both assigned based on the child’s postcode registered on the Scottish national vaccination call-recall system, SIRS). The SIMD breaks Scotland into 6,976 small areas of similar population size and assigns one of 5 SIMD quintiles based on indicators of deprivation including income, education, and housing, with 1 representing the most deprived areas and 5, the least [19]. We defined geographical areas by the Health and Social Care Partnership (HSCP) in which the child lives. Within Scotland, there are 31 HSCPs that provide integrated health and social care to their population. Additional information on inclusion and exclusion criteria can be found in S2 File.

English data were extracted from the ImmForm system, for January 2019 (representing the first extract for prelockdown period) to September 2020 (representing the final extract for postlockdown period), which automatically receives monthly aggregate data on vaccine uptake from 92% to 95% of English GP practices, provided by GP System Suppliers. These data are validated and analysed by Public Health England to check completeness, query any anomalous results, and are used to describe epidemiological trends, as well as being used directly locally by the NHS for performance management. Data were available for immunisation uptake at age 6 months (each dose of the 6-in-1 immunisation) and 18 months (first MMR) only.

Statistical methods

The primary outcome examined was the change in percentage uptake, within 4 weeks of eligibility, of each of the immunisations of interest between baseline uptake rates in 2019 and during the lockdown period for Scotland as a whole and by geographical areas or level of deprivation. Of secondary interest were comparisons between 2019 and the other time points listed above. Broadly comparable analyses were conducted to examine the primary outcome for England as a whole. Due to differences in data collection methods and age of child at data extraction point, comparisons between Scottish and English data were descriptive only.

To compare uptake rates between time periods, aggregate binary logistic regression modelling was conducted, using vaccination status (vaccinated versus unvaccinated) as the dependent variable, and time period as the explanatory variable. Separate analyses were carried out for each vaccine and country. When comparing HSCP or deprivation, an additional interaction with HSPC or SIMD quintile was included in the model. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for uptake in the period of interest compared to the 2019 baseline. Given the nature of the aggregated data available, no adjusting for potential confounders or effect modifiers was possible. Further methodological details can be found in S2 File.

All analyses and generation of figures were performed using R/R Studio (4.0.3). All code is publicly available via the EAVE II GitHub page (https://github.com/EAVE-II). Scottish data can be accessed via the PHS wider impacts dashboard https://scotland.shinyapps.io/phs-covid-wider-impact/. The English data used are included in the Supporting information, and any further queries should be directed to EarlyChildhoodBaseline@phe.gov.uk.

Ethics and funding

Ethical approval for this specific study was not required as we have used publicly available, anonymised, aggregated data. This study is reported as per the REporting of studies Conducted using Observational Routinely collected Data (RECORD) guideline (S3 File) [20]. No specific funding was received for this project; RM is funded by the Health Data Research UK BREATHE hub.

Results

Data were available for the outcome of 439,754 vaccine invitations in Scotland and 4.08 million for England across all time periods. As many infants or children would be eligible for multiple immunisations during the study, these figures do not represent individual participant numbers. Detailed demographic data are not routinely collected and were therefore not available. For context, S1 Table shows population data from the relevant national records offices for births in Scotland and England by sex, maternal age, and maternal country of birth from 2015 to 2020. It is expected that these data are broadly representative of the children included in this study.

All CIs presented are 95% CIs, and ORs are compared to the baseline year 2019 unless otherwise stated.

Preschool immunisation uptake increased during the lockdown period in Scotland

Across Scotland, the percentage of preschool children receiving their immunisations within 4 weeks of becoming eligible increased during the lockdown period for all 5 immunisations (Fig 1, Table 1, S2 Table). The change in percentage uptake compared to the 2019 baseline ranged from 1.3% for the first dose 6-in-1 (OR 1.28, CI 1.18 to 1.39) to 14.3% for the second dose MMR (OR 1.8, CI 1.74 to 1.87) (Table 1). Across all the immunisations visits, this equated to an additional 7,508 preschool immunisations being delivered in a timely manner over the lockdown period compared to the baseline rates of 2019. Uptake rates dipped immediately before the announcement of a national lockdown in mid-March 2020 (Fig 1), then peaked throughout June before starting to decrease. However, uptake remained significantly higher than 2019 during the postlockdown period (Fig 1, Table 1). Of note, prior to lockdown for both MMR doses, there was already a modest, increase in uptake compared to 2019 (Table 1).

Fig 1. Percentage of children in Scotland immunised within 4 weeks of eligibility.

Fig 1

(A) All doses 6-in-1 vaccine; (B) MMR vaccine across January to September 2020 in Scotland. Lockdown period = blue shaded area. For January and February, a single mean monthly value is plotted, and from March onwards, weekly uptake is shown (see S2 Table for full data). Dashed horizontal lines (—) indicated the mean uptake in 2019 of the immunisation with the corresponding colour. The increase in uptake during the lockdown period was statistically significant (see Table 1 for details). MMR, measles, mumps, and rubella.

Table 1. Uptake of preschool immunisations in Scotland by time period with OR compared to baseline of 2019.

Immunisation Time period % uptake within 4 weeks of eligibility (number received/total eligible) % point change from 2019 OR for uptake compared to 2019 (95% CI) p-Value
First dose 6-in-1 2019 94 (47,567/50,609) NA NA NA
Pre LD 93.3 (10,103/10,761) −0.7 0.98 (0.9–1.07) 0.68
LD 95.3 (16,371/17,133) 1.3 1.28 (1.18–1.39) <0.001
Post LD 94.6 (8,075/8,531) 0.6 1.13 (1.02–1.25) 0.02
Second dose 6-in-1 2019 84.8 (43,221/50,975) 0 NA NA
Pre LD 84.4 (9,106/10,698) −0.4 1.03 (0.97–1.09) 0.39
LD 89.7 (15,443/17,222) 4.9 1.56 (1.47–1.65) <0.001
Post LD 88.7 (7,459/8,412) 3.9 1.4 (1.31–1.51) <0.001
Third dose 6-in-1 2019 73 (37,266/51,083) NA NA NA
Pre LD 72.8 (8,276/11,394) −0.2 0.98 (0.94–1.03) 0.49
LD 82.1 (14,039/17,093) 9.1 1.7 (1.63–1.78) <0.001
Post LD 80.3 (6,555/8,172) 7.3 1.5 (1.42–1.59) <0.001
First dose MMR 2019 65.2 (33,935/52,015) NA NA NA
Pre LD 67.4 (7,782/11,370) 2.2 1.16 (1.11–1.21) <0.001
LD 78.4 (14,482/18,463) 13.2 1.94 (1.86–2.02) <0.001
Post LD 74.5 (6,740/9,047) 9.3 1.56 (1.48–1.64) <0.001
Second dose MMR 2019 51.8 (25,844/49,940) NA NA NA
Pre LD 53.1 (6,390/11,495) 1.3 1.17 (1.12–1.22) <0.001
LD 66.1 (11,303/17,145) 14.3 1.8 (1.74–1.87) <0.001
Post LD 63.1 (5,171/8,196) 11.3 1.59 (1.52–1.67) <0.001

p-Value calculated using aggregate binary logistic regression, statistically significant changes in uptake compared to 2019 are shaded green. p-Value rounded to 2 decimal places.

CI, confidence interval; LD, lockdown; MMR, measles, mumps, and rubella; NA, not applicable; OR, odds ratio; Post LD, postlockdown; Pre LD, prelockdown.

Variation in uptake of preschool immunisations by geographical area

Baseline data from 2019 showed the percentage uptake of preschool immunisations within 4 weeks of eligibility varied widely by geographical HSCP and immunisation (Fig 2, S1 Fig, S3 Table). In keeping with the rise in mean uptake across Scotland for all vaccines, the percentage of children immunised in most HSCP increased between 2019 and lockdown. However, not all followed this pattern with a minority demonstrating a fall in uptake (Fig 2, S1 Fig, S3 Table). Care must be taken when interpreting percentage results from the island HSCPs (Shetland Islands, Orkney Islands, and Western Isles) given the very small numbers of children involved (S3 Table).

Fig 2. Percentage uptake by Scottish HSCP in 2019 and statistically significant increases between 2019 and “lockdown”.

Fig 2

Left-hand side maps show baseline mean percentage uptake by HSCP in Scotland in 2019, and right-hand side maps show percentage point difference between 2019 and lockdown for areas in which the difference was statistically significant for each vaccine. Grey areas indicated HSCP where there were no statistically significant changes in uptake between 2019 and lockdown. Note that in Grampian, the second MMR dose is delivered at a later age; therefore, data for this area are recorded as “nonapplicable” (further details in S2 File). The full dataset can be found in S3 Table. Base layer map available from https://spatialdata.gov.scot/geonetwork/srv/eng/catalog.search;jsessionid=714BD98E15D22A8116824CA25B30DC02#/metadata/ac5e870f-8fc2-4c21-8b9c-3bd2311a583f, which contains public sector information licenced under the Open Government Licence v3.0. HSCP, Health and Social Care Partnership; LD, lockdown; MMR, measles, mumps, and rubella; Wks, weeks.

For individual HSCP, the statistical significance of the change in uptake varied by immunisation (Fig 2, S3 Table). Despite a general trend of improvement for the first 6-in-1 vaccine, we found a significant change for only 8 of the 31 HSCP, mainly centred around the more densely populated, urban central belt of Scotland (Glasgow City, Edinburgh, Stirling and Clackmannanshire, East Dunbartonshire, Falkirk, Fife, South Lanarkshire, South Ayrshire; Fig 2). However, this pattern evolved with the different immunisation visits and with almost all HSCP showing a rise in uptake for both MMR immunisations, with percentage point increases as high as 30% (Angus, 74.1% versus 43.8%, OR 3.38,CI 2.61 to 4.37) (Fig 2, S3 Table).

Preschool immunisation uptake increased across all deprivation levels

Percentage uptake within 4 weeks of becoming eligible rose across all SIMD quintiles, between 2019 and lockdown, for all immunisations (Fig 3). The magnitude of this rise varied by quintile and vaccine (S2 Fig, S4 Table) from 0.3% (SIMD 4, first 6-in-1 dose, OR 1.1, 95% CI 0.9 to 1.3) to 16.2% (SIMD 5, second MMR dose, OR 2.1, 95% CI 1.9 to 2.3). The increase in uptake between 2019 and lockdown was statistically significant for all except first dose 6-in-1 for the least deprived quintiles (4 and 5) (S4 Table). In the postlockdown period, percentage uptake remained significantly higher than the 2019 baseline for all quintiles for each vaccine except for the first 6-in-1 dose, in which only the most deprived quintile retained a significant increase (S2 Fig, S4 Table).

Fig 3. Mean percentage immunised by SIMD quintile in Scotland.

Fig 3

(A) 6-in-1 vaccine; (B) MMR vaccine for Scotland. See S2 Fig and S4 Table for absolute percentage rise compared to 2019 and significance levels. LD, lockdown; MMR, measles, mumps, and rubella; PostLD, postlockdown; PreLD, prelockdown; SIMD, Scottish Index of Multiple Deprivation.

In keeping with previous observations [21], children in the least deprived quintiles were more likely to be immunised and this relationship was broadly maintained throughout the study period (Fig 3 and S3). While all quintiles improved uptake between 2019 and lockdown, whether the inequality between most and least deprived increased or decreased varied by vaccine type. For all doses of the 6-in-1 vaccine, there was a tendency to a convergent improvement, i.e., the gap in percentage uptake between the quintiles lessened, while for both MMR doses, there was further divergence in uptake rates between most and least deprived (Fig 3, S4 Fig, S5 Table). The interaction of SIMD quintile and time period was nonsignificant for all 6-in-1 doses; that is to say all SIMD quintiles improved equally for this immunisation (S5 Table). However, for the first MMR dose, the improvement in uptake was statistically greater for SIMD quintiles 3 to 5 compared to SIMD 1, and for the second MMR dose, SIMD 5 showed a significantly larger increase in uptake between 2019 and lockdown (S5 Table). This suggests that for the MMR immunisation, the factors leading to an improvement in uptake had greater positive impact for children living in less deprived areas.

“Catch-up” immunisation rates and comparison with data from England

Thus far, the Scottish data presented have related to children receiving their immunisations as per the recommended schedule (within 4 weeks of the child becoming eligible by age), representing a “gold standard” in which the child is protected as early as possible. It is recognised that some children will receive their immunisations after this point. This “catch-up” effect can be seen in uptakes rate for all Scottish children by the time they reached between 6 and 8 months (6-in-1), 16 months (first MMR), or 3 years 8 months (second MMR) (Fig 4A). Those becoming eligible during lockdown showed minimal change in this longer-term measure of uptake for the 3 doses of the 6-in-1 immunisation, a small increase in uptake of the first MMR, and a more substantial increase in uptake of the second MMR (S6 Table). These data suggest that while lockdown was associated with a beneficial effect on timely uptake of all infant and preschool immunisations, the impact on longer term or final achieved uptake was more variable, possibly reflecting a ceiling effect on maximal uptake, for the earliest immunisations.

Fig 4. Percentage of children up to date at 6/18 months in Scotland and England.

Fig 4

Overall mean percentage of children immunised by approximately 6 months of age (all doses of 6 in1, see y-axis for specific ages) or 16–18 months (first MMR) for Scotland and England. Each bar contains children who became eligible for the immunisation of interest during the time period indicated. (A) Scotland, (B) England *** p-value < 0.001, * p-value <0.05, ns, not significant. p-values calculated using binary logistic regression. LD, lockdown; MMR, measles, mumps, and rubella; PostLD, postlockdown; PreLD, prelockdown.

For England, broadly equivalent data were available for children aged 6 months (all doses 6-in-1) and 18 months (first dose MMR) who had become eligible for their immunisations during the time periods of interest (Fig 4B, S7 Table). These data demonstrated a small but statistically significant fall in uptake for all the immunisations in the lockdown periods compared to 2019, ranging from 0.5% (first dose 6-in-1, 95.8% versus 96.3%, OR 0.89, CI 0.86 to 0.91) to 2.1% (third dose 6-in-1, 86.6% versus 88.7, OR 0.82, CI 0.81 to 0.83) (S7 Table). However, much of the fall in uptake took place in the prelockdown period, particularly for the third dose 6-in-1, with a gradual recovery seen over the lockdown period itself (S4 Fig). A general trend towards falling MMR uptake can also be seen to predate the COVID-19 pandemic (S4 Fig).

Discussion

We found that early uptake of infant and preschool immunisations (within 4 weeks of a child becoming eligible) rose significantly for the duration of the first lockdown period in Scotland, resulting in thousands more children receiving their immunisations at the scheduled time. Encouragingly, positive results were seen across all levels of deprivation, though some geographical variations were observed across Scotland. Improvement was also seen in longer term uptake of the first and second MMR immunisations (immunisation within 4 months of becoming eligible) in the lockdown period. Findings in England differed, with a small fall in longer-term uptake of immunisations observed for the lockdown period.

The Scottish data in particular challenge the early predictions of an adverse effect of lockdown measures on childhood immunisation uptake and demonstrate the importance of continued surveillance throughout the various phases of pandemic control measures. From these data alone, we are unable to fully determine what changes in both the barriers and motivators to vaccination may have led to this result; however, examining previous research can offer some suggestions. While the concept of vaccine hesitancy is a popular media topic, previous studies have shown that the reasons given by parents for not vaccinating their children are often much more practical. A prepandemic report by the Royal Society for Public Health in the UK found that the major barriers for parents who wanted to immunise their children were timing and availability of appointments and childcare duties [22]. For those who actively chose not to immunise their children, fear of side effects was a key concern and the negative effects of social media are increasing [22]. The lockdown has had a major effect on parental working patterns with almost 9 million UK employees furloughed and millions more working from home, often with the additional tasks of managing childcare as schools and nurseries were closed [23]. While this had made life significantly more challenging for many, more flexible working patterns may have made attending immunisation appointments easier for some.

Jarchow-MacDonald and colleagues [24] from NHS Lothian (which consists of HSCPs Edinburgh, West Lothian, East Lothian, and Midlothian) have suggested that ensuring the accessibility of immunisation centres, either by public transport or by providing mobile services to shielding families, was important in maintaining uptake during the pandemic, as was directly communicating with families with a preappointment phone call and reminder postcards. This gave families an opportunity to discuss the immunisation with a healthcare professional, a strategy that has been showed to be important in addressing parental concerns [25]. In fact, the reminder alone may have been sufficient to encourage parents to attend the first appointment [26]. The clear commitment of the Scottish Government to maintain the immunisation programme was also felt to be an important factor [24].

In England, Bell and colleagues [27] conducted a large-scale online survey of parents of children under the age of 18 months to assess their experiences of accessing immunisations during the early part of the UK lockdown (19 April to 11 May 2020). They highlighted the uncertainty of some families about whether the immunisation service was continuing, particularly among non-white ethnic groups. While most felt it was important that their child was immunised on time, Bell and colleagues reported that many parents felt the risk of catching a vaccine-preventable infectious disease was reduced due to limited mixing with others. This suggests that an enhanced appreciation of the utility of immunisation was not a major motivator for parents to ensure they attended the immunisation appointments. These issues may well be reflected in the fall in immunisation uptake in England during the earlier part of lockdown reported here, and a delay in receiving the first dose 6-in-1 may well led to delays in subsequent doses, meaning that the infants were unable to “catch up” by 6 months of age.

Other factors, which may have had an impact on promoting timely immunisation uptake, could include a reduction in fever, cough, and colds, which may otherwise have caused parents to delay immunisations. Though specific data on this point are lacking, a significant fall in the detection of Rhinovirus in adults was observed in 2020 compared to 2019 [28], suggesting that “normal” childhood respiratory infections are likely to have decreased. More work is required to fully dissect the key factors in improving timely preschool immunisation uptake in Scotland. Clarity and publicity about the continuation of the immunisation programmes, telephone reminders, and the opportunity to discuss with healthcare professions seem likely to have had the most impact. We plan to use the data generated in this study to inform future work investigating these factors, including geographical differences and the introduction of policies such as reminders and publicity campaigns.

It is important to acknowledge the limitations of the data presented, many of which arise from opportunistically using routinely collected data rather than that obtained from a specific study design. The SIRS electronic system is well established and captures data on the entire child population in Scotland. However, the aggregate surveillance data derived from the system that we could access lacked detailed information on several potentially important factors, not least of which was ethnicity, which is known to affect both immunisation uptake and attitudes towards immunisation. [29]. As shown in S1 Table, the proportion of mothers born outside the UK is relatively low in Scotland (16.3% to 17.7% between 2015 and 2020) and is almost half that of England (28.4% to 30.2%). It may not be appropriate to extrapolate these data to countries with a significantly different ethnic makeup, and it is plausible that some of the difference seen between the Scottish and English data could be due to these factors.

In using the mean percentage of the entire year 2019 as our baseline comparator, we potentially run the risk of confusing normal seasonal variation in immunisation uptake with the impact of lockdown measures. Ideally, direct weekly or monthly comparisons would be made between 2019 and 2020, though these data are not available. The enhanced detail and frequency of collection of immunisation uptake data and rapid dissemination (through the COVID dashboard) was in response to the pandemic and therefore only began in March 2020. However, quarterly trends published for previous years including 2019 do not show major difference in uptake throughout the year and in fact show a gradual decline in uptake year on year since 2015 [30]. In addition, it is possible that 2020 uptake rates have been underestimated, due to a lag in data entry into SIRS, which would particularly affect the “catch-up” rates (Fig 4A).

Therefore, caution must be taken not to overinterpret the results presented here or extrapolate to significantly different populations with varying baseline immunisation uptakes rates and less robust immunisation programmes, the organisation of which may have been adversely affected by the pandemic. Nevertheless, this study has efficiently and quickly produced useful and valid results, which have the potential to aid the development of future research and guide policy. The positive findings regarding immunisation uptake despite the extreme circumstances of the COVID-19 pandemic and associated lockdowns (in Scotland at least) is an important message to send to support public and professional confidence in the preschool immunisation programme and help normalise timely immunisation uptake for both parents and health services. Improving public and professional confidence is particularly vital given the current importance of promoting vaccination against SARS-CoV-2. Despite these encouraging data, it is not possible to ascertain from the numbers alone, which are the key contributing factors to improving uptake. This is a key avenue of future research as lessons learnt can then be taken forward to optimise future immunisation programmes, both within the pandemic setting and beyond. In addition, we have not yet assessed the potential impact of improved early immunisation uptake on rates of vaccine preventable diseases. Any observed changes in vaccine-preventable diseases (for example, pertussis in young babies) would be heavily confounded by the changes in behaviour such as social distancing and isolation for symptoms such as cough. However, of the 5 vaccinations, there did appear to be an increase in overall coverage for the second MMR; therefore, monitoring trends in measles cases as we move fully out of COVID-related restrictions may be of interest, though we would not be able to infer causation.

The ongoing COVID-19 pandemic continues to stretch health services and adversely affect all areas of life, with children disproportionately bearing the burden of the indirect consequences of pandemic control measures such as the closure of schools and limited social contact. However, opportunities have also been created in terms of enhanced surveillance of health programmes. In this study, we have used such data to investigate the effect of the pandemic on infant and preschool immunisation uptake. We have demonstrated that a robust child immunisation service can continue to deliver high and even increasing uptake rates. Families will respond despite the many difficulties they face, to ensure that children continue to be protected again vaccine-preventable diseases. The challenge now is to use and expand on this knowledge to promote future vaccination programmes, including those targeting SARS-CoV-2.

Supporting information

S1 Fig

Percentage uptake by Scottish HSCP for 2019 (pale orange) and LD (dark orange) with HSCP ordered by uptake for 2019 (note: this varies by immunisation). Dashed horizontal lines indicated the mean uptake for all of Scotland for the time period of the corresponding colour. HSCP, Health and Social Care Partnership; LD, lockdown.

(TIF)

S2 Fig

Absolute percentage change in uptake in Scotland compared to 2019 for each immunisations and SIMD for each time period (A = Pre LD, B = LD, C = Post LD). Significance rates varied by immunisation and SIMD; for details, see S3 Table. LD, lockdown; Post LD, postlockdown; Pre LD, prelockdown; SIMD, Scottish Index of Multiple Deprivation.

(TIF)

S3 Fig

Combined OR plot with 95% CI comparing each SIMD quintile (2–5) to SIMD 1-most deprived for 2019 (dark blue) and LD (light blue). Data for Scotland only. CI, confidence interval; LD, lockdown; OR, odds ratio; SIMD, Scottish Index of Multiple Deprivation.

(TIF)

S4 Fig. Percentage of children in England immunised by 6 months of age (first, second, and third dose 6-in-1) or 18 months of age (first dose MMR) from January 2019 to September 2020.

The start and end of the lockdown period is indicated by the purple shaded area. MMR, measles, mumps, and rubella.

(TIF)

S1 Table. Summary statistics for all live births in Scotland and England 2015–2020 from the National Records of Scotland (Scotland) and Office of National Statistics (England).

Note this table gives an overview of the population as these data were not available for the individuals within the study. The date range encompasses the oldest to youngest children potentially included. For example, those born in 2015 would be eligible for the second dose MMR in 2019 and those born in early August 2020 would be eligible for the first dose 6-in-1 during the “postlockdown” time period. However, this does not account for children who may have migrated into/out of the areas since birth. Percentages are rounded to 1 decimal place. MMR, measles, mumps, and rubella.

(DOCX)

S2 Table. Percentage uptake of each immunisation for Scotland by year (2019), month (January and February 2020), or week as per data availability.

W/B, week beginning.

(DOCX)

S3 Table

A-E: Percentage uptake, percent point change in uptake compared to 2019 and significance level for this change for each HSCP at each time period. Each table shows results for a different immunisation. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. Results were considered significant if p-value <0.05 and 95% CI did not include 1. Statistically significant p-values are shaded green, and significant results for the 2019–LD comparisons are plotted on Fig 2. CI, confidence interval; HSCP, Health and Social Care Partnership; LD, lockdown; NA, not applicable; OR, odds ratio; PostLD, postlockdown; PreLD, pre lockdown.

(DOCX)

S4 Table. Uptake of preschool immunisations by time period and SIMD and percent point change in uptake compared to baseline 2019.

OR and 95% CI shown are for change in uptake compared to 2019. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. Statistically significant change in uptake compared to 2019 are shaded green. CI, confidence interval; LD, lockdown, NA, not applicable; OR, odds ratio; SIMD, Scottish Index of Multiple Deprivation.

(DOCX)

S5 Table. To assess whether the differences between change in uptake were statistically significant between SIMD quintiles, the interaction between time period and SIMD quintile was added into the model.

The baseline comparisons showed are for time period 2019 and deprivation quintile SIMD 1. If the 95% CI did not include 1, the interaction of time period and SIMD was considered statistically significant, that is; there was a significant difference in the level of change (2019- time period) between the deprivation quintile and SIMD 1. For example, the increase in uptake during lockdown for SIMD 5 was statistically greater than the increase in uptake for SIMD 1. The ROR can be used to calculate the OR for uptake compared to the baseline levels by multiplying the ROR with the relevant OR in S3 table. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; ns, not statistically significant (coloured green), interaction was statistically significant; OR, odds ratio; ROR, ratio of odds ratio, calculated by taking the exponential function of the coefficient of the interaction term from the interaction model; SIMD, Scottish Index of Multiple Deprivation.

(DOCX)

S6 Table. Scotland.

Uptake of preschool immunisations at an older age by time period and point percentage change from 2019 with OR and 95% CI compared to baseline of 2019. Children are categorised into the time period at which they became eligible for the immunisation as before and uptake data were extracted at a later stage when they reached the ages indicated in the immunisation column. Statistically significant changes are coloured green. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; NA, not applicable; OR, odds ratio.

(DOCX)

S7 Table. England.

Uptake of preschool immunisations at an older age by time period and point percentage change from 2019 with OR and 95% CI compared to baseline of 2019. Children are categorised into the time period at which they became eligible for the immunisation as before and uptake data were extracted at a later stage when they reached the ages indicated in the immunisation column. Statistically significant changes are coloured green. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; NA, not applicable; OR, odds ratio.

(DOCX)

S1 File. Childhood immunisation V1.0 final analysis plan.

(DOCX)

S2 File. Supplemental methods.

(DOCX)

S3 File. RECORD plus STROBE checklist.

(DOCX)

Acknowledgments

We thank Public Health Scotland for making the data publicly available and acknowledge the support of the HDR UK BREATHE Hub and EAVE II collaborators.

Abbreviations

CI

confidence interval

COVID-19

Coronavirus Disease 2019

DTaP/IPV/Hib/HepB

diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B

HSCP

Health and Social Care Partnership

MMR

measles, mumps, and rubella

OR

odds ratio

SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus 2

SIMD

Scottish Index of Multiple Deprivation

WHO

World Health Organization

Data Availability

All relevant data are within the manuscript and its Supporting Information files and further Scottish data can be accessed via the Public health Scotland wider impacts dashboard https://scotland.shinyapps.io/phs-covid-wider-impact/. The English data used is included in the supplementary information. Any further queries regarding the data on ImmForm should be directed to EarlyChildhoodBaseline@phe.gov.uk. All code used in the analyses is publicly available via the EAVE II GitHub page (https://github.com/EAVE-II).

Funding Statement

This analysis was part of the EAVE II project. EAVE II is funded by the Medical Research Council (MC_PC_19075), https://mrc.ukri.org/, with the support of BREATHE: the Health Data Research Hub for Respiratory Health (MC_PC_19004), https://www.hdruk.ac.uk/helping-with-health-data/health-data-research-hubs/breathe, which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Decision Letter 0

Louise Gaynor-Brook

23 Jul 2021

Dear Dr McQuaid,

Thank you for submitting your manuscript entitled "Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by .

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Louise Gaynor-Brook, MBBS PhD

Associate Editor

PLOS Medicine

Decision Letter 1

Louise Gaynor-Brook

29 Sep 2021

Dear Dr. McQuaid,

Thank you very much for submitting your manuscript "Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data" (PMEDICINE-D-21-03163R1) for consideration at PLOS Medicine.

Your paper was evaluated by three independent reviewers, including a statistical reviewer, and was discussed among all the editors here and with an academic editor with relevant expertise. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Oct 20 2021 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Louise Gaynor-Brook, MBBS PhD

Associate Editor, PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Comments from the Academic Editor:

As the reviewers indicate, there is a need of data and descriptions of the secondary effects of the pandemic on health services, coverage and health outcomes. A possible increase in coverage is of interest among all other reports of negative indirect effects - although it may be difficult to draw inferences that are relevant to other settings.

Requests from the editors:

General comments:

Throughout the paper, please adapt reference call-outs to the following style: "... likely to be profound [7,8]." (noting the absence of spaces within the square brackets).

Data availability:

PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available, without restrictions on access, in a public repository or as Supporting Information at the time of article publication, provided it is legal and ethical to do so.

Where the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries - please note that a study author cannot be the contact person for data requests.

Abstract Background: The final sentence should clearly state the study question.

Abstract Methods and Findings:

Please provide brief demographic details of the study population (e.g. sex, age, ethnicity, etc)

Please include the number of participants and dates between which the study took place.

Please define abbreviations at first use e.g. DTaP/IPV/Hib/HepB, MMR

Please clarify whether CIs presented are 95% CIs.

Where ORs are provided, please specify the comparison group.

In the last sentence of the Abstract Methods and Findings section, please describe 2-3 of the main limitations of the study's methodology."

Abstract Conclusions:

Please begin your Abstract Conclusions with "In this study, we observed ..." or similar, to summarize the main findings from your study, without overstating your conclusions. Please emphasize what is new and address the implications of your study, being careful to avoid assertions of primacy.

Please avoid using ‘effect’, which should be used only if causality can be inferred, i.e., from an RCT.

Author Summary:

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

Introduction:

Line 104 - please temper assertions of primacy by adding ‘to the best of our knowledge’ or similar

Methods:

Thank you for appending your analysis plan. Please cite this early in the Methods section. Changes in the analysis-- including those made in response to peer review comments-- must be identified as such in the Methods section of the paper, with rationale. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data-driven.

Please add the following statement, or similar, to the Methods: "This study is reported as per the REporting of studies Conducted using Observational Routinely-collected Data (RECORD) guideline (S1 Checklist)." When completing the checklist, please use section and paragraph numbers, rather than page numbers which will likely no longer correspond to the appropriate sections after copy-editing.

Line 205 - please refer to the specific supplementary file where further details can be found.

Results:

Please provide a table showing the baseline characteristics of the study population (as Table 1).

Please report the number of individuals included in your study.

Please clarify whether CIs presented are 95% CIs.

Where ORs are presented, please specify the comparison group.

Discussion:

Please present and organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Please remove all subheadings within your Discussion e.g. Limitations and other considerations

Figures:

Please define all abbreviations used in the figure legend of each figure.

Please consider avoiding the use of red and green in order to make your figure more accessible to those with colour blindness.

Fig. 1, Fig S1, Fig 3, Fig S5 - Please clarify what is meant by the time in brackets on the label of your y axis.

Tables:

When a p value is given, please specify the statistical test used to determine it in the table legend.

Please define all abbreviations used in the table legend of each table.

References:

Please ensure that journal name abbreviations match those found in the National Center for Biotechnology Information (NCBI) databases, and are appropriately formatted and capitalised.

Please also see https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references for further details on reference formatting. For example, 6 authors should be named prior to ‘et al’.

Supplementary files:

Please see https://journals.plos.org/plosmedicine/s/supporting-information for our supporting information guidelines.

Comments from the reviewers:

Reviewer #1: Review of Manuscript Number: PMEDICINE-D-21-03163R1, "Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data"

Overall Impression

This study serves to describe the impact of COVID-19 lockdowns in England and Scotland on routine preschool immunizations. Using routinely collected data from Public Health Scotland and ImmForm in England, the authors found consistent increases in timely vaccination rates during the COVID-19 pandemic lockdown in Scotland for all five vaccine doses examined. In England, authors found decreases in the fraction of children who were up-to-date for their childhood vaccines during the lockdown period compared to 2019.

This analysis contributes to a growing body of research quantifying the impact of the COVID-19 pandemic on routine childhood immunizations. While much of the research focuses on early phases of the pandemic and finds substantial disruption, this article provides an example (in Scotland) of a program experiencing increases in immunization during this period, the opposite effect.

Strengths of this manuscript include substantial data availability and disaggregation by vaccine dose, age, geography, and deprivation variables in Scotland. The data in England was more limited, however, and could not be compared directly to that of Scotland. Additionally this study was observational in nature and did not address the underlying drivers or reasons for these patterns and trends.

I recommend that the editors publish this manuscript after minor revisions. Specific recommendations are included below.

Major Issue

1. The authors describe that they use "aggregate binary logistic regression" with "vaccination status (vaccinated vs unvaccinated) as the dependent variable" (lines 192-94). It is unclear to me the definition of this method and the exact formulation used. If aggregate percentages were used, how were these values weighted in the analysis? Please provide additional detail so that this analysis could be replicated.

Minor Issues

2. In Figure 1 the authors provide the annual uptake for 2019, monthly uptake for Jan and Feb of 2020, and weekly update for March to September 2020. While this plot is helpful, it masks any seasonal variation that may be expected in vaccine delivery. It would be helpful to see the monthly or weekly pattern of vaccine delivery in 2019 to compare to what was observed in 2020. The authors also mention this in their limitations (lines 354-59); this analysis fails to account for seasonality in vaccine delivery.

3. The y-axis on figure 4 makes it very hard to notice the small differences in the bars. Could you use a smaller y-scale (for example 75 to 100) or a different type of chart to visualize this data?

4. This manuscript provides consistent and convincing data to suggest that vaccine delivery significantly increased during the COVID-19 lockdown in Scotland. The authors also acknowledge that the nature of this data do not allow for detailed understanding of the precise reasons for that trend. For these results to be most useful, it would be important for clinicians and policy-makers to understand the precise drivers of success to apply them in settings where COVID-19 continues to disrupt routine health services or in order to build more robust and resilient vaccine delivery systems in other countries. The authors provide two primary hypotheses—A) that flexible work increased appointment attendance (lines 379-83) and B) that accessibility and pre-appointment reminders increased uptake (lines 384-93). It would be helpful to supplement this analysis with qualitative or contextual data to support these hypotheses or provide additional strategies that led to the success observed. I would also like to know if the strategies described in B) were unique to the COVID-19 lockdown period? What was the timeline for these interventions? The authors also provide some hypotheses for the decrease in England (lines 394-405) but do not explain why these factors were abated in Scotland. What were the specific program differences between England and Scotland that may have led to these differences in uptake?

5. The authors acknowledge in the results that the positive impact on vaccine uptake in Scotland was primarily in the "timeliness" of vaccines and that "the impact on longer term or final achieved uptake was more variable, possibly reflecting a ceiling effect on maximal uptake, for the earliest immunisations" (294-307). Based on this description and the results of this analysis, it appears that the COVID-19 lockdown may have promoted more prompt vaccinations but not overall vaccine coverage. Could the authors provide a quantitative analysis on the impact of prompt vaccination? Especially during the COVID-19 pandemic when pandemic-related behavior change such as reduced physical contact likely decreased the transmission of many infectious diseases, is vaccination a few weeks or even months earlier likely to have a big impact on the transmission of vaccine-preventable diseases?

Reviewer #2: 1. The results could be potentially biased when the underlying trend and seasonal patterns (e.g. if there is an increasing trend in the uptake, and or the update proportion decrease in the holiday season in December) are not controlled. Since weekly and/or monthly data are available, I would recommend to extend the study period (e.g. Add data of 2017 and 2018 ) and employ a more robust interrupted time series design in order to control for the underlying secular trend and seasonal variation in the pre-Covid-19 period. Although the author points out in the limitation that quarterly trends published for previous years including 2019 do not show major difference in uptake throughout the year and in fact show a gradual decline in uptake since 2015, I would suggest to analyze and graphically demonstrate the trend of the weekly/monthly uptake proportion for the years before the pandemic.

2. The author talked little about how they handle missing data. As shown in Figure 2, missingness (or does not missingness here represents not significant change? The author needs to clarify this) mainly exited in regions with higher baseline uptake proportion. This missingness not at random may confound the overall estimates.

3. I would suggest to the title of Fig 2 because it not only shows the baseline mean update proportion. What's the difference between "Absolute % change" and "% point change" ?

4. For figure 4, I would suggest to reset the limits of y axis or present the % of unvaccinated as the difference between the four periods in the current figure is hardly noticeable.

5. For figure S1, I would suggest to add the geographic areas with missing data.

6. The code is not available from the Github page. This needs to be updated accordingly.

7. The author may consider sensitivity analysis examining uptake within 2 and 6 weeks of eligibility

Reviewer #3: The authors assess the impact of the COVID-19 associated lockdowns in the UK and Scotland on pre-school vaccinations rates. Their results are reassuring in that they found that the coverage rates were higher in Scotland during the lockdown and while the UK did experience a decline, it was relatively small. My comments are provided in the attached draft manuscript and mostly focus on the the figures and tables. Several of the figures need considerable editing to be understandable and able to stand alone. I also suggest the authors considered omitting a few of the supplemental figures that aren't needed. Overall the manuscript is well written and contains relevant data. I hope the authors take the time to ensure their figures effectively highlight and clarify their results.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: PMEDICINE-D-21-03163_R1_reviewed.pdf

Decision Letter 2

Louise Gaynor-Brook

10 Jan 2022

Dear Dr. McQuaid,

Thank you very much for re-submitting your manuscript "Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data" (PMEDICINE-D-21-03163R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by three reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Jan 17 2022 11:59PM.   

Sincerely,

Louise Gaynor-Brook, MBBS PhD

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

Abstract Methods and Findings:

Line 49 - please revise to ‘We conducted an observational study’ or similar

Line 65 - please define OR and CI at first use

Author Summary:

In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

Results:

Line 269 - please revise to “14.3% for”

Discussion:

Line 398 - please remove ‘in fact’

Line 401 - please remove ‘Although’ at the beginning of the sentence

Line 433 - please revise to ‘suggesting’

Line 464 - please revise to ‘significantly’

Line 473 - please revise ‘vital given in’

Figures:

All figures - please specify country in the legend

Fig S1 - please indicate sections A and B within the figure itself

Fig S4 - dashed blue lines appear to be missing from the figure itself

Fig S2 - Please note that figures cannot be reproduced from sources that are not CC-BY. Please be sure to check the usage rights.

Tables:

S2 Table - please specify country in the legend

Comments from Reviewers:

Reviewer #1: I am satisfied with the edits made to this manuscript in response to review and believe it should be accepted for publication.

Reviewer #2: We thank the author for answering reviewers's question and revising the paper.

1. The title and legends of all Figures are missing

Reviewer #3: The authors addressed all of my concerns in their revised manuscript.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Louise Gaynor-Brook

17 Jan 2022

Dear Dr McQuaid, 

On behalf of my colleagues and the Academic Editor, Prof. Lars Åke Persson, I am pleased to inform you that we have agreed to publish your manuscript "Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data" (PMEDICINE-D-21-03163R3) in PLOS Medicine.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Sincerely, 

Louise Gaynor-Brook, MBBS PhD 

Associate Editor, PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig

    Percentage uptake by Scottish HSCP for 2019 (pale orange) and LD (dark orange) with HSCP ordered by uptake for 2019 (note: this varies by immunisation). Dashed horizontal lines indicated the mean uptake for all of Scotland for the time period of the corresponding colour. HSCP, Health and Social Care Partnership; LD, lockdown.

    (TIF)

    S2 Fig

    Absolute percentage change in uptake in Scotland compared to 2019 for each immunisations and SIMD for each time period (A = Pre LD, B = LD, C = Post LD). Significance rates varied by immunisation and SIMD; for details, see S3 Table. LD, lockdown; Post LD, postlockdown; Pre LD, prelockdown; SIMD, Scottish Index of Multiple Deprivation.

    (TIF)

    S3 Fig

    Combined OR plot with 95% CI comparing each SIMD quintile (2–5) to SIMD 1-most deprived for 2019 (dark blue) and LD (light blue). Data for Scotland only. CI, confidence interval; LD, lockdown; OR, odds ratio; SIMD, Scottish Index of Multiple Deprivation.

    (TIF)

    S4 Fig. Percentage of children in England immunised by 6 months of age (first, second, and third dose 6-in-1) or 18 months of age (first dose MMR) from January 2019 to September 2020.

    The start and end of the lockdown period is indicated by the purple shaded area. MMR, measles, mumps, and rubella.

    (TIF)

    S1 Table. Summary statistics for all live births in Scotland and England 2015–2020 from the National Records of Scotland (Scotland) and Office of National Statistics (England).

    Note this table gives an overview of the population as these data were not available for the individuals within the study. The date range encompasses the oldest to youngest children potentially included. For example, those born in 2015 would be eligible for the second dose MMR in 2019 and those born in early August 2020 would be eligible for the first dose 6-in-1 during the “postlockdown” time period. However, this does not account for children who may have migrated into/out of the areas since birth. Percentages are rounded to 1 decimal place. MMR, measles, mumps, and rubella.

    (DOCX)

    S2 Table. Percentage uptake of each immunisation for Scotland by year (2019), month (January and February 2020), or week as per data availability.

    W/B, week beginning.

    (DOCX)

    S3 Table

    A-E: Percentage uptake, percent point change in uptake compared to 2019 and significance level for this change for each HSCP at each time period. Each table shows results for a different immunisation. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. Results were considered significant if p-value <0.05 and 95% CI did not include 1. Statistically significant p-values are shaded green, and significant results for the 2019–LD comparisons are plotted on Fig 2. CI, confidence interval; HSCP, Health and Social Care Partnership; LD, lockdown; NA, not applicable; OR, odds ratio; PostLD, postlockdown; PreLD, pre lockdown.

    (DOCX)

    S4 Table. Uptake of preschool immunisations by time period and SIMD and percent point change in uptake compared to baseline 2019.

    OR and 95% CI shown are for change in uptake compared to 2019. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. Statistically significant change in uptake compared to 2019 are shaded green. CI, confidence interval; LD, lockdown, NA, not applicable; OR, odds ratio; SIMD, Scottish Index of Multiple Deprivation.

    (DOCX)

    S5 Table. To assess whether the differences between change in uptake were statistically significant between SIMD quintiles, the interaction between time period and SIMD quintile was added into the model.

    The baseline comparisons showed are for time period 2019 and deprivation quintile SIMD 1. If the 95% CI did not include 1, the interaction of time period and SIMD was considered statistically significant, that is; there was a significant difference in the level of change (2019- time period) between the deprivation quintile and SIMD 1. For example, the increase in uptake during lockdown for SIMD 5 was statistically greater than the increase in uptake for SIMD 1. The ROR can be used to calculate the OR for uptake compared to the baseline levels by multiplying the ROR with the relevant OR in S3 table. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; ns, not statistically significant (coloured green), interaction was statistically significant; OR, odds ratio; ROR, ratio of odds ratio, calculated by taking the exponential function of the coefficient of the interaction term from the interaction model; SIMD, Scottish Index of Multiple Deprivation.

    (DOCX)

    S6 Table. Scotland.

    Uptake of preschool immunisations at an older age by time period and point percentage change from 2019 with OR and 95% CI compared to baseline of 2019. Children are categorised into the time period at which they became eligible for the immunisation as before and uptake data were extracted at a later stage when they reached the ages indicated in the immunisation column. Statistically significant changes are coloured green. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; NA, not applicable; OR, odds ratio.

    (DOCX)

    S7 Table. England.

    Uptake of preschool immunisations at an older age by time period and point percentage change from 2019 with OR and 95% CI compared to baseline of 2019. Children are categorised into the time period at which they became eligible for the immunisation as before and uptake data were extracted at a later stage when they reached the ages indicated in the immunisation column. Statistically significant changes are coloured green. p-Values calculated using aggregate binary logistic regression and rounded to 2 decimal places. CI, confidence interval; LD, lockdown; NA, not applicable; OR, odds ratio.

    (DOCX)

    S1 File. Childhood immunisation V1.0 final analysis plan.

    (DOCX)

    S2 File. Supplemental methods.

    (DOCX)

    S3 File. RECORD plus STROBE checklist.

    (DOCX)

    Attachment

    Submitted filename: PMEDICINE-D-21-03163_R1_reviewed.pdf

    Attachment

    Submitted filename: Response to reviewers only.docx

    Attachment

    Submitted filename: PMEDICINE-D-21-03163R2 Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files and further Scottish data can be accessed via the Public health Scotland wider impacts dashboard https://scotland.shinyapps.io/phs-covid-wider-impact/. The English data used is included in the supplementary information. Any further queries regarding the data on ImmForm should be directed to EarlyChildhoodBaseline@phe.gov.uk. All code used in the analyses is publicly available via the EAVE II GitHub page (https://github.com/EAVE-II).


    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES